Background:

Metabolic differences between human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) and smoking-associated HNSCC may partially explain differences in prognosis. The former relies on mitochondrial oxidative phosphorylation (OXPHOS) while the latter relies on glycolysis. These differences have not been studied in blood.

Methods:

We extracted metabolites using untargeted liquid chromatography high-resolution mass spectrometry from pretreatment plasma in a cohort of 55 HPV-associated and 82 smoking-associated HNSCC subjects. Metabolic pathway enrichment analysis of differentially expressed metabolites produced pathway-based signatures. Significant pathways (P < 0.05) were reduced via principal component analysis and assessed with overall survival via Cox models. We classified each subject as glycolytic or OXPHOS phenotype and assessed it with survival.

Results:

Of 2,410 analyzed metabolites, 191 were differentially expressed. Relative to smoking-associated HNSCC, bile acid biosynthesis (P < 0.0001) and octadecatrienoic acid beta-oxidation (P = 0.01), were upregulated in HPV-associated HNSCC, while galactose metabolism (P = 0.001) and vitamin B6 metabolism (P = 0.01) were downregulated; the first two suggest an OXPHOS phenotype while the latter two suggest glycolytic. First principal components of bile acid biosynthesis [HR = 0.52 per SD; 95% confidence interval (CI), 0.38–0.72; P < 0.001] and octadecatrienoic acid beta-oxidation (HR = 0.54 per SD; 95% CI, 0.38–0.78; P < 0.001) were significantly associated with overall survival independent of HPV and smoking. The glycolytic versus OXPHOS phenotype was also independently associated with survival (HR = 3.17; 95% CI, 1.07–9.35; P = 0.04).

Conclusions:

Plasma metabolites related to glycolysis and mitochondrial OXPHOS may be biomarkers of HNSCC patient prognosis independent of HPV or smoking. Future investigations should determine whether they predict treatment efficacy.

Impact:

Blood metabolomics may be a useful marker to aid HNSCC patient prognosis.

Head and neck squamous cell carcinoma (HNSCC) can be divided into two groups that are clinically, genetically, and possibly metabolically distinct: human papillomavirus (HPV)-associated HNSCC and smoking-associated HNSCC (sometimes viewed as HPV-unassociated). The former consists of HPV-positive oropharyngeal tumors with little to no patient smoking history, while the latter consists of HPV-negative oropharyngeal and all other HNSCC sites from patients with a substantial smoking history (i.e., >10 pack-years); HPV-positive oropharyngeal cancer patients with a substantial smoking history are likely a mix of HPV-associated and smoking-associated HNSCC. Clinically, HPV-associated HNSCC is less aggressive, responds better to treatment, and on average patients live two-to-seven times longer than smoking-associated HNSCC (1). Genetically, “hotspot” locations in the PIK3CA oncogene are mutated in HPV-associated tumors, while TP53 tumor suppressor loss mutations are in most smoking-associated tumors (2, 3). These genes are known to regulate tumor metabolism. For instance, wild-type p53 dampens glycolysis and promotes mitochondrial oxidative phosphorylation (OXPHOS) by regulating glucose transporters (GLUT) and key enzymes in the glycolysis pathway (4).

It has been hypothesized that loss or inactivation of p53 may promote the Warburg effect (5), that is, the reprogramming of tumor metabolism to favor glycolysis at the expense of OXPHOS (6). Noticed in the 1920s by Otto Warburg, this atypical metabolic state provides the energy and macromolecules for rapid proliferation and metastasis (7–10). It links to nearly all hallmarks of cancer (11). The Warburg effect can be seen, literally, via 18F-Fluorodeoxyglucose PET (18F-FDG-PET; ref. 12). Higher tumor uptake of the fluorescent glucose marker means higher glycolytic activity, which is directly associated with poor prognosis and treatment resistance in HNSCC (13, 14). In fact, the Warburg effect may be a factor in HNSCC treatment resistance. Increased glycolysis and decreased OXPHOS promotes resistance to ionizing radiotherapy (15) and studies suggest modulating glycolysis may resensitize a tumor (16, 17). Recent studies in HNSCC cell lines suggest that a Warburg-like metabolic phenotype differentiates HPV-positive from HPV-negative cells (18, 19). The Warburg effect may thus explain, in part, the differences in presentation, progression, and survival observed between these HNSCC groups. However, it has yet to be investigated as a potential blood biomarker.

Our goal was to investigate the metabolic differences of HPV-associated HNSCC relative to smoking-associated HNSCC in pretreatment patient plasma using untargeted high-resolution metabolomics (HRM) and test whether those differences were prognostic of overall survival independent of HPV status. HRM is the comprehensive measurement of small molecules arising from metabolic reactions occurring in a biospecimen—that is, metabolites (20). It uses gas or liquid chromatography paired with high-resolution mass spectrometry to quantify thousands of metabolites via their mass-to-charge ratio (m/z; ref. 21). The metabolites are matched to reference databases (22) or identified with authentic standards (23). While single metabolite investigations used to be the norm, recent advances in high-throughput measurement, bioinformatics, and pathway analysis have shifted the field toward a systems-biology approach, gaining further insight into disease via dysregulated metabolic pathways and profiles (24–26).

Cohort

This was a prospective cohort of patients with HNSCC recruited at radiation oncology clinics affiliated with Emory University Hospital (Atlanta, GA) from 2013 to 2016 before undergoing intensity-modulated radiotherapy (IMRT) with or without chemotherapy (27). In this analysis, all patients gave written informed consent to participate in the parent study and all ancillary studies. Recruitment and data collection for the parent study and the current ancillary study were guided by the ethical principles of the Belmont Report and reviewed and approved by the Emory University Institutional Review Board. Inclusion criteria were histological HNSCC with no distant metastasis, ≥21 years of age, and no evidence of uncontrolled metabolic, hematologic, cardiovascular, renal, hepatic or neurologic disease. Patients with simultaneous primaries or major psychiatric disorders were excluded. Demographic and clinical variables were collected through chart review and standardized questionnaires at study entry. Prior to IMRT, blood was collected into chilled EDTA tubes for the immediate isolation of plasma. Plasma was separated by centrifugation at 1,000 × g for 10 minutes at 4°C then aliquoted into siliconized polypropylene tubes and stored at −80°C.

Classification of HPV-associated and smoking-associated HNSCC

HPV status was ascertained via review of the tumor pathology report. We deemed a subject HPV positive if p16 was positive or if HPV DNA was detected. Smoking status was ascertained via questionnaire of tobacco habits; the questionnaire did not allow calculation of pack-years. We defined our smoking-associated HNSCC group as all current or former smokers with a non-oropharyngeal or HPV-negative oropharyngeal tumor; non-oropharyngeal tumors are rarely attributed to HPV (28) and thus not uniformly tested. We defined our HPV-associated HNSCC group as all subjects who were HPV-positive never smokers. We endeavored to mitigate group misclassification thus we deliberately excluded HPV-positive oropharyngeal cancer patients with a smoking history. We believe these patients are a mix of smoking-associated and HPV-associated HNSCC and by including them would introduce misclassification. In a 2010 seminal article, Ang and colleagues demonstrated that HPV-positive oropharyngeal cancer patients who are smokers with >10 pack-years—deemed as having “Intermediate risk” for survival—are clinically distinct from the “Low risk” group (i.e., HPV-positive, ≤10 pack-years) and the “High risk” group (i.e., HPV-negative, >10 pack-years; ref. 29).

Overall survival

Vital status was ascertained via linkage to the Georgia Comprehensive Cancer Registry maintained at Emory University (Atlanta, GA). Overall survival was defined as the time from study entry to death by any cause, or to the last contact up to August 2020.

HRM of blood plasma

We used LC/MS protocols developed at the Emory Clinical Biomarkers Laboratory (30, 31). Frozen aliquots from randomized samples were removed from −80°C, thawed, and extracted with ice-cold acetonitrile. Supernatants were added to a 4°C autosampler. Each sample was analyzed in triplicate (10 μL) using hydrophilic interaction liquid chromatography (HILIC) with positive electrospray ionization and Fourier transform Orbitrap high-resolution mass spectrometry (Dionex Ultimate 3000, Q-Exactive HF, Thermo Fisher Scientific). Analyte separation was achieved using a 2.1 mm × 100 mm × 2.6 μm Accucore HILIC column (Thermo Fisher Scientific) and a gradient elution of 2% formic acid, water, and acetonitrile starting at 10%, 10%, 80%, for 1.5 minutes with a linear increase to 10%, 80%, 10% at 6 minutes and held for 4 minutes per injection.

The high-resolution mass spectrometer operated at 120,000 resolution and an m/z range of 85.0000–1275.0000. Probe temperature, capillary temperature, sweep gas, and S-Lens RF levels were 200°C, 300°C, 1 arbitrary units (AU), and 45 AU, respectively. Positive tune for sheath gas, auxiliary gas, sweep gas, and spray voltage settings were 45 AU, 25 AU, and 3.5 kV, respectively. Spectral peaks were extracted and aligned using apLCMS (32) and xMSanalyzer (33). Mass, retention time, and ion intensity were recorded for unique m/z spectral features. Features with a coefficient of variation ≥75% were removed. Feature intensities were median summarized across triplicates and corrected for any batch effects (34). Features were log2 transformed and quantile normalized. We restricted our investigation to m/z features annotated via the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Human Metabolome (HMDB) reference databases (22).

Statistical analysis

We identified differences in metabolic pathways of HPV-associated HNSCC relative to smoking-associated HNSCC via feature selection (step 1) followed by metabolic pathway enrichment analysis (step 2). We reduced each significant pathway via principal component analysis (PCA; step 3) and estimated the first principal components (PC) with overall patient survival via Cox models (step 4). On the basis of the pathway results, we classified each patient, post hoc, into a binary glycolytic or OXPHOS metabolic phenotype and estimated that classification with overall survival (step 5).

Step 1: We selected m/z features that differentiated HPV-associated versus smoking-associated HNSCC in any of three models routinely used in untargeted metabolomics analyses: age at study entry, sex, and race adjusted logistic regression using a Benjamini–Hochberg FDR P < 0.10; Partial least squares discriminant analysis using a variable importance in projection >2; Support vector machine using recursive feature elimination. Step 2: We identified enriched metabolic pathways from the features using Mummichog, a pathway analysis tool that maps m/z to KEGG metabolic networks and uses resampling to obtain a Fisher exact test P value (24)—a similar methodology to gene set enrichment analysis. Pathways with ≥3 metabolite hits and P < 0.05 met our threshold for statistical significance. We note the identification level (35) of the pathway metabolites and plot a heatmap. Step 3: We performed PCA on the metabolites that comprised each significant pathway. Step 4: The first PC for each pathway was z-standardized and regressed on overall patient survival using Cox proportional hazards adjusted for HPV and smoking status, age at study entry, sex, race, tumor stage and patient Eastern Cooperative Oncology Group (ECOG) status; we found no statistically significant interaction by these variables. Further adjustment for body mass index (BMI), alcohol consumption, marriage status, treatment, feeding tube, and time of blood draw did not change our results and were not included in final models. The HRs estimated the increase in mortality per 1 SD change in the pathway-specific PC. We conducted a subanalysis restricting to oropharyngeal and non-oropharyngeal carcinoma subjects to investigate whether results hold across tumor site. Step 5: We dichotomized the PCs at their study medians and used the three most significant pathways to classify each subject as having a glycolytic or an OXPHOS phenotype (i.e., if ≥2 of the 3 pathways indicated glycolysis the patient was classified that way and vice versa with OXPHOS). We regressed the glycolytic versus OXPHOS phenotype on overall survival with a Cox model and plotted a Kaplan–Meier survival curve.

We used publicly available R packages for feature selection (xmsPANDA 1.1.76; ref. 36), pathway analysis (Mummichog 2.0; ref. 24), and metabolite annotation (xmsAnnotator 1.3.2; ref. 22). PCA used the “prcomp” R package. Cox regression used SAS version 9.4 (37).

Compared with smoking-associated, the HPV-associated HNSCC subjects on average were younger (56.8 vs. 60.1 years), more obese (29.0 vs. 26.1 kg/m2), White (87% vs. 72%), and male (89% vs. 62%; Table 1). As expected, the HPV-associated tumors were predominantly in the oropharynx (96%) and less advanced (29% were stage IV vs. 64% for smoking-associated). Also expected, the smoking-associated subjects had higher mortality than HPV-associated group [unadjusted HR = 7.6; 95% confidence interval (CI) = 2.8–25.5; P < 0.001; Kaplan–Meier curve in Supplementary Fig. S1].

Table 1.

Demographics and clinical characteristics of HPV-associated and smoking-associated HNSCC groups.

HPV-associated (n = 55)Smoking-associated (n = 82)P
Deatha Reported death 8% 24 34%  
 Living/censored 47 92% 47 66%  
 
Survival time (months) Mean (SD) 46.3 17.8 37.3 20.6 0.01 
 
Age (years) Mean (SD) 56.8 7.8 60.1 10.5 0.05 
 
BMI (kg/m2Mean (SD) 29.0 4.7 26.1 5.3 0.001 
 
Sex Men 49 89% 51 62% <0.001 
 Women 11% 31 38%  
 
Race White 48 87% 59 72% 0.03 
 All others 13% 23 28%  
 
Alcohol usea <1 drink per wk 28 52% 49 60% 0.32 
 > = 1 drink per wk 26 48% 32 40%  
 
Tumor site Oropharynx 53 96% 12 15% <0.001 
 All others 4% 70 85%  
 
Tumor stagea I—III 38 70% 29 41% <0.001 
 IV 16 30% 52 59%  
 
ECOG statusa 0 (fully active) 39 74% 24 32% <0.001 
 1 (restricted) 13 25% 38 50%  
 2 (unable to work) 2% 14 18%  
 
Treatment Radiotherapy only 10 18% 17 21% 0.43 
 Chemoradiotherapy 45 82% 65 79%  
HPV-associated (n = 55)Smoking-associated (n = 82)P
Deatha Reported death 8% 24 34%  
 Living/censored 47 92% 47 66%  
 
Survival time (months) Mean (SD) 46.3 17.8 37.3 20.6 0.01 
 
Age (years) Mean (SD) 56.8 7.8 60.1 10.5 0.05 
 
BMI (kg/m2Mean (SD) 29.0 4.7 26.1 5.3 0.001 
 
Sex Men 49 89% 51 62% <0.001 
 Women 11% 31 38%  
 
Race White 48 87% 59 72% 0.03 
 All others 13% 23 28%  
 
Alcohol usea <1 drink per wk 28 52% 49 60% 0.32 
 > = 1 drink per wk 26 48% 32 40%  
 
Tumor site Oropharynx 53 96% 12 15% <0.001 
 All others 4% 70 85%  
 
Tumor stagea I—III 38 70% 29 41% <0.001 
 IV 16 30% 52 59%  
 
ECOG statusa 0 (fully active) 39 74% 24 32% <0.001 
 1 (restricted) 13 25% 38 50%  
 2 (unable to work) 2% 14 18%  
 
Treatment Radiotherapy only 10 18% 17 21% 0.43 
 Chemoradiotherapy 45 82% 65 79%  

Abbreviations: HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; IQR, interquartile range; SD, standard deviation; wk, week.

aIndicates a variable that was missing in ≥1 subject.

From 16,342 extracted features, 3,075 matched to KEGG or HMDB reference databases. After filtering for missing values, 2,410 were left for analysis. The three feature selection models identified 191 metabolites that were differentially expressed between HPV-associated and smoking-associated HNSCC (Supplementary Table S1; Supplementary Fig. S2).

From 91 pathways, pathway enrichment analysis identified six statistically significant metabolic pathways from the 191 metabolites (Fig. 1; Supplementary Table S2). Notably, all six pathways are relevant to mitochondrial OXPHOS or glycolysis—demonstrating a potential Warburg-like metabolic phenotype. The pathways related to OXPHOS, that is, bile acid biosynthesis (P < 0.0001), 21-carbon steroid metabolism (P = 0.007), and octadecatrienoic acid beta-oxidation (P = 0.012), were upregulated in HPV-associated HNSCC and downregulated in smoking-associated HNSCC. The pathways related to glycolysis, that is, galactose metabolism (P = 0.001), vitamin B6 metabolism (P = 0.014), and starch and sucrose metabolism (P = 0.02), were the opposite. Four pathways implicated in HNSCC did not meet significance but followed the Warburg-like pattern: selenoamino acid metabolism (P = 0.065), phosphatidylinositol phosphate (P = 0.076), and hexose phosphorylation (P = 0.091) were upregulated in smoking-associated HNSCC, while omega-3 fatty acid metabolism (P = 0.065) was upregulated in HPV-associated HNSCC.

Figure 1.

The metabolic pathways that were upregulated (green) or downregulated (blue) in HPV-associated relative to smoking-associated HNSCC. P values for each pathway are labeled. The dashed red line indicates statistical significance at the P < 0.05 level. The pathways were identified through the metabolic pathway enrichment analysis program, Mummichog version 2.0, with 191 metabolites that differentiated HPV-associated HNSCC from smoking-associated HNSCC in three feature selection models (multivariable logistic regression, partial least squares discriminant analysis, and support vector machines). The first number following the pathway is the number of significant metabolites in the pathway found in the 191. The second number is the number of metabolites Mummichog mapped to that pathway from the 2,410 total.

Figure 1.

The metabolic pathways that were upregulated (green) or downregulated (blue) in HPV-associated relative to smoking-associated HNSCC. P values for each pathway are labeled. The dashed red line indicates statistical significance at the P < 0.05 level. The pathways were identified through the metabolic pathway enrichment analysis program, Mummichog version 2.0, with 191 metabolites that differentiated HPV-associated HNSCC from smoking-associated HNSCC in three feature selection models (multivariable logistic regression, partial least squares discriminant analysis, and support vector machines). The first number following the pathway is the number of significant metabolites in the pathway found in the 191. The second number is the number of metabolites Mummichog mapped to that pathway from the 2,410 total.

Close modal

For subsequent analyses, we reduced the six pathways to four because of metabolite overlap (five of the six 21-carbon steroid metabolites overlapped with bile acid biosynthesis, and all three of the starch and sucrose metabolites overlapped with galactose). In Table 2, we annotate the 23 metabolites that comprised the bile acid biosynthesis (n = 9), galactose metabolism (n = 6), octadecatrienoic acid beta-oxidation (n = 5), and vitamin B6 metabolism (n = 3) pathways. Twelve features were unique (* = identified via an authentic standard): adenosine 5′-monophosphate*, dihydroxy-5beta-cholestane, cholic acid, galactosylglycerol, 3-ketolactose, lactose*, inosine diphosphate, raffinose*, stachyose*, pyridoxamine*, pyridoxic acid*, and pyridoxamine 5-phosphate. The other 11 had multiple matches. A heatmap shows the relative intensity of each metabolite and the pathways between HPV-associated and smoking-associated HNSCC (Fig. 2). In general, HPV-associated patients had higher levels of bile acid biosynthesis and octadecatrienoic acid beta-oxidation and lower levels of galactose metabolism and vitamin B6 metabolism; the smoking-associated patients with HNSCC had the opposite.

Table 2.

Metabolite annotation for 23 metabolites mapped to four different metabolic pathways that differentiate HPV-associated HNSCC from smoking-associated HNSCC.

m/zTimeaKEGG compound IDbCompound namecAdductID leveldFCePCf
Bile acid biosynthesis pathway 
 348.0692 102 C00020 Adenosine 5′-monophosphate M+H[1+] −0.83 −0.18 
 403.3568 36 C06340; C05451; C15610; C05500; C05502; C15519; C13550; C03594 Hydroxycholesterol M+H[1+] 1.05 0.35 
 405.3726 36 C05452 Dihydroxy-5beta-cholestane M+H[1+] 1.73 0.39 
 409.2942 36 C00695 Cholic acid M+H[1+] 1.20 0.23 
 419.3517 36 C06341; C05458; C05453; C05501; C15518; C15520; CE5530; C05499; C05445 Dihydroxycholesterol M+H[1+] 1.37 0.38 
 421.3673 37 C05454; C05444 Trihydroxy-5beta-cholestane M+H[1+] 2.54 0.37 
 435.3466 36 C04554; CE4872; C01301 Dihydroxy-5beta-cholestanate M+H[1+] 0.81 0.38 
 437.3615 37 CE0232; C05446; CE1272 Tetrahydroxy-5beta-cholestane M+H[1+] 0.93 0.35 
 453.3571 36 CE4874; CE1277; CE1278; CE1279 5beta-cholestane-pentol M+H[1+] 1.25 0.30 
Galactose metabolism pathway 
 277.0894 74 C05401 Galactosylglycerol M+Na[1+] −1.60 0.12 
 341.1106 41 C05403 3-Ketolactose M+H[1+] 2.79 −0.40 
 365.1054 99 C00243 Lactose M+Na[1+] −1.59 0.51 
 429.023 27 C00104 Inosine diphosphate M+H[1+] −0.59 0.10 
 527.1585 153 C00492 Raffinose M+Na[1+] −1.33 0.52 
 689.2079 249 C01613 Stachyose M+Na[1+] −1.50 0.54 
Octadecatrienoic acid beta-oxidation pathway 
 237.1486 36 CE5311; CE5323 Hydroxy-tetradeca-trienoic acid M[1+] 0.32 0.52 
 239.1641 36 CE5313; CE5312; CE5325; CE5324 Hydroxy-tetradeca-dienoic acid M[1+] 0.47 0.49 
 263.1639 37 CE5314; CE5326 Hydroxy-hexadeca-tetraenoic acid M[1+] 1.38 0.37 
 265.1796 35 CE5315; CE5316; CE5327; CE5328 Hydroxy-hexadeca-trienoic acid M[1+] 1.13 0.39 
 281.1748 37 CE5321; CE5309 3-oxo-hydroxy-hexadeca-dienoic acid M[1+] 0.69 0.44 
Vitamin B6 metabolism pathway 
 169.0971 43 C00534 Pyridoxamine M+H[1+] −0.47 0.78 
 184.0597 46 C00847 Pyridoxic acid M+H[1+] −0.94 0.38 
 249.0611 59 C00647 Pyridoxamine 5′-phosphate M+H[1+] 0.29 −0.51 
m/zTimeaKEGG compound IDbCompound namecAdductID leveldFCePCf
Bile acid biosynthesis pathway 
 348.0692 102 C00020 Adenosine 5′-monophosphate M+H[1+] −0.83 −0.18 
 403.3568 36 C06340; C05451; C15610; C05500; C05502; C15519; C13550; C03594 Hydroxycholesterol M+H[1+] 1.05 0.35 
 405.3726 36 C05452 Dihydroxy-5beta-cholestane M+H[1+] 1.73 0.39 
 409.2942 36 C00695 Cholic acid M+H[1+] 1.20 0.23 
 419.3517 36 C06341; C05458; C05453; C05501; C15518; C15520; CE5530; C05499; C05445 Dihydroxycholesterol M+H[1+] 1.37 0.38 
 421.3673 37 C05454; C05444 Trihydroxy-5beta-cholestane M+H[1+] 2.54 0.37 
 435.3466 36 C04554; CE4872; C01301 Dihydroxy-5beta-cholestanate M+H[1+] 0.81 0.38 
 437.3615 37 CE0232; C05446; CE1272 Tetrahydroxy-5beta-cholestane M+H[1+] 0.93 0.35 
 453.3571 36 CE4874; CE1277; CE1278; CE1279 5beta-cholestane-pentol M+H[1+] 1.25 0.30 
Galactose metabolism pathway 
 277.0894 74 C05401 Galactosylglycerol M+Na[1+] −1.60 0.12 
 341.1106 41 C05403 3-Ketolactose M+H[1+] 2.79 −0.40 
 365.1054 99 C00243 Lactose M+Na[1+] −1.59 0.51 
 429.023 27 C00104 Inosine diphosphate M+H[1+] −0.59 0.10 
 527.1585 153 C00492 Raffinose M+Na[1+] −1.33 0.52 
 689.2079 249 C01613 Stachyose M+Na[1+] −1.50 0.54 
Octadecatrienoic acid beta-oxidation pathway 
 237.1486 36 CE5311; CE5323 Hydroxy-tetradeca-trienoic acid M[1+] 0.32 0.52 
 239.1641 36 CE5313; CE5312; CE5325; CE5324 Hydroxy-tetradeca-dienoic acid M[1+] 0.47 0.49 
 263.1639 37 CE5314; CE5326 Hydroxy-hexadeca-tetraenoic acid M[1+] 1.38 0.37 
 265.1796 35 CE5315; CE5316; CE5327; CE5328 Hydroxy-hexadeca-trienoic acid M[1+] 1.13 0.39 
 281.1748 37 CE5321; CE5309 3-oxo-hydroxy-hexadeca-dienoic acid M[1+] 0.69 0.44 
Vitamin B6 metabolism pathway 
 169.0971 43 C00534 Pyridoxamine M+H[1+] −0.47 0.78 
 184.0597 46 C00847 Pyridoxic acid M+H[1+] −0.94 0.38 
 249.0611 59 C00647 Pyridoxamine 5′-phosphate M+H[1+] 0.29 −0.51 

Abbreviations: FC, fold change; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; m/z, mass-to-charge; PC, principal component; time, retention time in seconds.

aMetabolite extraction retention time in seconds.

bMummichog-based mapping to KEGG database identification number.

cm/z features that matched to multiple reference metabolites are named as specifically as the matching allowed.

dIdentification Confidence Level for metabolite annotation (23, 35) (1 = laboratory confirmed standard, 3 = tentative structural identification with a match to a reference database, 4 = molecular formula identification via isotope abundance distribution, charge state, adduct determination).

elog2 fold change association with HPV-associated HNSCC relative to smoking-associated HNSCC.

fStandardized loading factor for the first principal component of each metabolic pathway.

Figure 2.

Hierarchical clustering heatmap of HPV-associated (HPV) and smoking-associated (SMK) HNSCC and 23 z-transformed metabolites that comprised the four metabolic pathways: bile acid biosynthesis (n = 9 metabolites), galactose metabolism (n = 6), octadecatrienoic beta-oxidation (n = 5), and vitamin B6 (n = 3). The patients with HPV-associated HNSCC, in general, have higher levels of bile acid biosynthesis and octadecatrienoic acid beta-oxidation metabolites (red) and lower levels of galactose metabolism and vitamin B6 metabolism metabolites (blue) relative to the smoking-associated patients. The smoking-associated patients with HNSCC, in general, have the opposite, higher levels of galactose metabolism and vitamin B6 metabolism metabolites and lower levels of bile acid biosynthesis and octadecatrienoic acid beta-oxidation metabolites.

Figure 2.

Hierarchical clustering heatmap of HPV-associated (HPV) and smoking-associated (SMK) HNSCC and 23 z-transformed metabolites that comprised the four metabolic pathways: bile acid biosynthesis (n = 9 metabolites), galactose metabolism (n = 6), octadecatrienoic beta-oxidation (n = 5), and vitamin B6 (n = 3). The patients with HPV-associated HNSCC, in general, have higher levels of bile acid biosynthesis and octadecatrienoic acid beta-oxidation metabolites (red) and lower levels of galactose metabolism and vitamin B6 metabolism metabolites (blue) relative to the smoking-associated patients. The smoking-associated patients with HNSCC, in general, have the opposite, higher levels of galactose metabolism and vitamin B6 metabolism metabolites and lower levels of bile acid biosynthesis and octadecatrienoic acid beta-oxidation metabolites.

Close modal

We reduced each pathway to its first PC and regressed that on overall mortality using adjusted Cox regression (PCA plots in Supplementary Fig. S3; standardized loading factors in Table 2). Three of the four pathways were significantly associated with overall mortality in unadjusted models (Table 3). The bile acid biosynthesis and the octadecatrienoic acid PCs were inversely associated with mortality (HR = 0.52 per SD; 95% CI, 0.38–0.72; P < 0.001; and HR = 0.54 per SD; 95% CI, 0.38–0.78; P < 0.001, respectively). The galactose PC was positively associated mortality (HR = 1.72 per SD; 95% CI, 1.09–2.72; P = 0.02); Kaplan–Meier curves in Supplementary Fig. S4). To clarify, a subject at the lowest 20th percentile in the bile acid PC would have one-third the mortality of a subject at the highest 20th percentile (HR = 0.52⁁1.68 SD = 0.33). Most importantly, the associations for bile acid and octadecatrienoic acid were independent of HPV status, smoking history, age at study entry, and sex (Table 3). In fact, bile acid biosynthesis remained statistically significant after further adjustment for race, tumor stage, and patient ECOG status (HR = 0.58 per SD; 95% CI, 0.37–0.92; P = 0.02). Restricting to tumor site had little effect on the bile acid biosynthesis pathway estimate but modest effects on the other pathways' estimates; fewer deaths among the oropharyngeal subjects may have precluded statistical significance (Table 3).

Table 3.

First PCs of metabolic pathways that differentiate HPV-associated HNSCC from smoking-associated HNSCC and their association with overall patient mortality via Cox models.

HRCIP
Bile acid biosynthesis first PC 
 Unadjusted model 0.52 (0.38–0.72) <0.001 
 HPV, smoking, age, sex adjusted model 0.52 (0.36–0.76) <0.001 
 Fully adjusted modela 0.58 (0.37–0.92) 0.02 
 Fully adjusted model among oropharyngeal tumor subjectsa 0.45 (0.17–1.17) 0.10 
 Fully adjusted model among non-oropharyngeal subjectsa 0.50 (0.27–0.94) 0.03 
Galactose first PC 
 Unadjusted model 1.72 (1.09–2.72) 0.02 
 HPV, smoking, age, sex adjusted model 1.28 (0.79–2.10) 0.32 
 Fully adjusted modela 1.21 (0.71–2.08) 0.48 
 Fully adjusted model among oropharyngeal tumor subjectsa 1.85 (0.53–6.49) 0.34 
 Fully adjusted model among non-oropharyngeal subjectsa 1.04 (0.60–1.80) 0.89 
Octadecatrienoic acid beta oxidation first PC 
 Unadjusted model 0.54 (0.38–0.78) <0.001 
 HPV, smoking, age, sex adjusted model 0.65 (0.44–0.97) 0.03 
 Fully adjusted modela 0.75 (0.51–1.10) 0.14 
 Fully adjusted model among oropharyngeal tumor subjectsa 0.29 (0.08–1.02) 0.05 
 Fully adjusted model among non-oropharyngeal subjectsa 0.74 (0.47–1.16) 0.19 
Vitamin B6 first PC 
 Unadjusted model 1.26 (0.86–1.86) 0.23 
 HPV, smoking, age, sex adjusted model 0.93 (0.61–1.41) 0.74 
 Fully adjusted modela 1.13 (0.75–1.72) 0.56 
 Fully adjusted model among oropharyngeal tumor subjectsa 0.51 (0.17–1.53) 0.23 
 Fully adjusted model among non-oropharyngeal subjectsa 1.35 (0.84–2.18) 0.22 
HRCIP
Bile acid biosynthesis first PC 
 Unadjusted model 0.52 (0.38–0.72) <0.001 
 HPV, smoking, age, sex adjusted model 0.52 (0.36–0.76) <0.001 
 Fully adjusted modela 0.58 (0.37–0.92) 0.02 
 Fully adjusted model among oropharyngeal tumor subjectsa 0.45 (0.17–1.17) 0.10 
 Fully adjusted model among non-oropharyngeal subjectsa 0.50 (0.27–0.94) 0.03 
Galactose first PC 
 Unadjusted model 1.72 (1.09–2.72) 0.02 
 HPV, smoking, age, sex adjusted model 1.28 (0.79–2.10) 0.32 
 Fully adjusted modela 1.21 (0.71–2.08) 0.48 
 Fully adjusted model among oropharyngeal tumor subjectsa 1.85 (0.53–6.49) 0.34 
 Fully adjusted model among non-oropharyngeal subjectsa 1.04 (0.60–1.80) 0.89 
Octadecatrienoic acid beta oxidation first PC 
 Unadjusted model 0.54 (0.38–0.78) <0.001 
 HPV, smoking, age, sex adjusted model 0.65 (0.44–0.97) 0.03 
 Fully adjusted modela 0.75 (0.51–1.10) 0.14 
 Fully adjusted model among oropharyngeal tumor subjectsa 0.29 (0.08–1.02) 0.05 
 Fully adjusted model among non-oropharyngeal subjectsa 0.74 (0.47–1.16) 0.19 
Vitamin B6 first PC 
 Unadjusted model 1.26 (0.86–1.86) 0.23 
 HPV, smoking, age, sex adjusted model 0.93 (0.61–1.41) 0.74 
 Fully adjusted modela 1.13 (0.75–1.72) 0.56 
 Fully adjusted model among oropharyngeal tumor subjectsa 0.51 (0.17–1.53) 0.23 
 Fully adjusted model among non-oropharyngeal subjectsa 1.35 (0.84–2.18) 0.22 

Abbreviations: CI, confidence interval; HPV, human papillomavirus; HR, Cox hazard ratio; PC, principal component.

aAdjusted for HPV and smoking status, age at study entry, sex, race, tumor stage, and patient ECOG status.

We used median dichotomized PCs from bile acid biosynthesis, galactose metabolism and octadecatrienoic acid beta-oxidation, to classify each subject with a glycolytic or mitochondrial OXPHOS phenotype (Fig. 3B). The Kaplan–Meier curve shows stark separation in survival (P < 0.0001) with the OXPHOS phenotype having a 93% estimated 3-year survival compared with 59% for the glycolytic phenotype (Fig. 3A). That survival difference was larger than what we observed for HPV-associated versus smoking-associated HNSCC, at 88% and 69%, respectively (Supplementary Fig. S1). The glycolytic versus OXPHOS Cox model showed the metabolic phenotype was significantly associated with mortality independent of HPV status and smoking history, age at study entry, sex, race, tumor stage, and patient ECOG status (HR = 3.17; 95% CI, 1.07–9.35; P = 0.04). Among HPV-associated subjects, 24% were classified as having the glycolytic phenotype (74% OXPHOS). Among the smoking-associated subjects, 34% of were classified as having the OXPHOS phenotype (66% glycolytic). This suggests that a glycolytic/OXPHOS phenotype may indeed be an independent prognostic biomarker and not merely an extension of HPV positivity or smoking status.

Figure 3.

The classification scheme and survival curve of the glycolytic versus OXPHOS metabolic phenotype. A, Kaplan–Meier survival curve of HNSCC subjects classified as having a glycolytic or mitochondrial OXPHOS metabolic phenotype. The estimated 3-year survival probability is 93% for subjects with an OXPHOS phenotype versus 59% for subjects with a glycolytic phenotype; the survival curves are statistically significant (log-rank P < 0.0001). The glycolytic versus OXPHOS Cox model estimated HR adjusted for HPV and smoking status, age, sex, race, tumor stage, and patient ECOG status is HR = 3.17 (95% CI:1.07–9.35; P = 0.04). B, The classification scheme for the glycolytic versus mitochondrial OXPHOS metabolic phenotype based on the median-dichotomized principal components of bile acid biosynthesis, octadecatrienoic acid beta-oxidation, and galactose metabolism (high = above median, low = below median). Each subject was classified glycolytic or OXPHOS based on the direction of ≥2 pathways.

Figure 3.

The classification scheme and survival curve of the glycolytic versus OXPHOS metabolic phenotype. A, Kaplan–Meier survival curve of HNSCC subjects classified as having a glycolytic or mitochondrial OXPHOS metabolic phenotype. The estimated 3-year survival probability is 93% for subjects with an OXPHOS phenotype versus 59% for subjects with a glycolytic phenotype; the survival curves are statistically significant (log-rank P < 0.0001). The glycolytic versus OXPHOS Cox model estimated HR adjusted for HPV and smoking status, age, sex, race, tumor stage, and patient ECOG status is HR = 3.17 (95% CI:1.07–9.35; P = 0.04). B, The classification scheme for the glycolytic versus mitochondrial OXPHOS metabolic phenotype based on the median-dichotomized principal components of bile acid biosynthesis, octadecatrienoic acid beta-oxidation, and galactose metabolism (high = above median, low = below median). Each subject was classified glycolytic or OXPHOS based on the direction of ≥2 pathways.

Close modal

In this prospective study, we observed a glycolytic versus mitochondrial OXPHOS metabolomic phenotype in HNSCC patient plasma that was associated with patient survival independent of key clinical factors including HPV and smoking. Relative to smoking-associated HNSCC, the metabolic pathways of bile acid biosynthesis and octadecatrienoic acid beta-oxidation were upregulated in HPV-associated patient plasma, while galactose metabolism and vitamin B6 metabolism were downregulated. These pathways help regulate the balance between OXPHOS and glycolysis—a balance frequently dysregulated in tumors, termed the Warburg effect.

Four prior studies have investigated serum or plasma metabolomics in patients with HNSCC (38–41), but to our knowledge, this is the first study to investigate metabolic differences of HPV-associated versus smoking-associated HNSCC. Perhaps the best comparison with our study is one by Jung and colleagues that studied HPV-positive versus HPV-negative HNSCC cell lines (18). Jung reported that HPV-positive cells rely on mitochondrial OXPHOS for energy metabolism while HPV-negative cells rely on glycolysis—results nearly identical to ours. Jung also found HPV-negative cells had increased levels of hypoxia-inducible factor-1α (HIF1α) and hexokinase II (HK-II), regulating enzymes of the hexose phosphorylation pathway, the first step in glycolysis. We found the same pathway upregulated in smoking-associated HNSCC though the result was not statistically significant. Importantly, Jung found that pharmacologic reversal of the glycolytic phenotype increased a cell's sensitivity to radiation therapy, suggesting a potential drug target. The similarity of our findings in patient blood to those in cell cultures suggests that circulating metabolites may be putative biomarkers of HNSCC tumor metabolism.

The Warburg-like plasma phenotype we observed has two parts. The first part was the dysregulated pathways related to glycolysis (i.e., galactose, starch, and sucrose, phosphatidylinositol phosphate, and hexokinase metabolism). Of our findings, glycolysis has the strongest prior evidence. It is a hallmark of HNSCC proliferation and survival, driven by oncogenic signaling (e.g., p53 loss and PI3KCA mutation), altered metabolic enzymes (e.g., GLUT-1, HK-II), and a hypoxic tumor environment (e.g., HIF1α; refs. 42, 43). Tumor hypoxia activates HIF1α, a transcription factor which increases a tumor's reliance on glycolysis while reducing mitochondrial OXPHOS (43). Using gene expression profiles, Keck and colleagues found hypoxia to be the discriminating feature of the basal HNSCC phenotype—a phenotype made up of HPV-negative smokers (44). Higher levels of glycolytic metabolites found in the plasma of smoking-associated patients with HNSCC may indeed be the downstream effect of tumor hypoxia. Hypoxia, and its glycolytic switch, is associated with aggressive disease (45), treatment failure (16), and poor survival (46) in HNSCC. Glycolytic metabolites in serum are significantly associated with HNSCC relapse (40), and in our study, upregulated glycolytic pathways in plasma were associated with a more aggressive tumor type and poor survival.

The second part of the Warburg-like phenotype we observed was the dysregulated pathways related to mitochondrial OXPHOS (i.e., bile acid biosynthesis, octadecatrienoic acid beta-oxidation, and omega-3 fatty acid metabolism). Bile acid biosynthesis was our most important finding. It was significantly upregulated in HPV-associated HNSCC and was positively associated with longer survival independent of HPV, smoking, and other clinical factors. It is understudied in HNSCC but deserves closer examination. Bile acids are synthesized in the liver from cholesterol to aid in the digestion of dietary fat. That process, however, is regulated via a host of nuclear receptor signaling pathways, notably FXR, TGR5, and PPAR, that are now recognized for suppressing cancer progression (47–50). Bile acids may also be related to tumor hypoxia as they have been shown to destabilize HIF1α in prostate, lung, and mammary cancer cell lines (51). Conversely, tumor hypoxia may represses CYP7A1, a key bile acid biosynthesis enzyme though many factors may affect this pathway (52).

Like bile acids, we found octadecatrienoic acid beta-oxidation (i.e., oxidation of 18-carbon lipids such as omega-3 and omega-6 fatty acids) upregulated in HPV-associated HNSCC and positively associated with longer survival independent of HPV and smoking. Pro-oncogenic pathways generally promote synthesis of fatty acids over oxidation because proliferating cells require lipids for biological membranes (53). Apart from lipoprotein(a), serum lipids appear to decrease as HNSCC progresses (54–59) and short-chain fatty acids may suppress HNSCC growth (60). Our findings agree that higher levels of lipid oxidation, in general, is a beneficial marker in HNSCC.

The Warburg effect is likely just one aspect of tumor metabolism linked to HNSCC progression. Molecular changes underlying HNSCC progression, such as p53 loss, EGFR mutation, and mutations in the signaling of PI3K-AKT, NOTCH1, and ALK1, parallel metabolic changes in the tumor (10, 61–64). Metabolomics may thus provide a rich source of HNSCC biomarkers particularly if metabolic reprogramming drives treatment resistance. Resistance to radiotherapy, cisplatin chemotherapy, and cetuximab immunotherapy may be directly related to reprogrammed glucose metabolism and mitochondrial-generated oxidative stress (15, 65, 66). Thus, metabolic biomarkers may give an early indication of HNSCC treatment efficacy and may be targets for novel metabolic therapies (10, 64).

The recruitment of the parent study limited our metabolome-wide analysis to HNSCC patient plasma and not tumor specimens. In addition, we did not have healthy controls as a comparison group. However, we analyzed plasma metabolic differences in two important clinical subtypes and assessed those differences with survival—something no prior study has done. The exclusion of HPV-positive patients with a smoking history gave us distinct HPV-associated and smoking-associated groups but may limit our generalizability. The extracted metabolites are likely influenced by recent diet and the subjects did not fast before blood draw. Information on diet was not available, but we did adjust the models for factors that influence diet such as smoking, alcohol, age, sex, BMI, and the time of the blood draw. Finally, untargeted metabolomics is a “shotgun” approach that measures the relative intensity of each mass-to-charge feature and we cannot be certain of the annotation, outside of laboratory standards (23). To improve confidence in our annotation, we restricted our analysis to metabolites matched to the KEGG and HMDB reference databases. However, a feature may match to multiple reference metabolites and we cannot distinguish between them.

In conclusion, we observed a Warburg-like metabolomic phenotype in HNSCC patient plasma that may aid patient prognosis. We expound on the metabolic pathways that differentiate HPV-associated from smoking-associated HNSCC, two groups who differ in their presentation, treatment sensitivity, and survival. We are working to independently validate the results we observed with bile acids, lipid oxidation, and galactose metabolism so that they warrant future investigations as predictors of treatment efficacy and as therapeutic targets for treatment resistant tumors.

R.C. Eldridge reports grants from Georgia Clinical and Translational Science Alliance during the conduct of the study. A.H. Miller reports non-financial support from Boehringer Ingelheim outside the submitted work. K.A. Higgins reports other support from AstraZeneca and grants and other support from RefleXion Medical during the conduct of the study. N.F. Saba reports receiving compensation for consult services to GSK, Merck, CUE, Kura, Vaccinex, and Pfizer. No disclosures were reported by the other authors.

R.C. Eldridge: Conceptualization, data curation, software, formal analysis, funding acquisition, methodology, writing–original draft, project administration, writing–review and editing. K. Uppal: Conceptualization, formal analysis, supervision, methodology, writing–review and editing. D.N. Hayes: Supervision, writing–review and editing. M.R. Smith: Writing–review and editing. X. Hu: Writing–review and editing. Z.S. Qin: Methodology, writing–review and editing. J.J. Beitler: Resources, writing–review and editing. A.H. Miller: Resources, writing–review and editing. E.C. Wommack: Data curation, project administration, writing–review and editing. K.A. Higgins: Resources, writing–review and editing. D.M. Shin: Resources, writing–review and editing. B. Ulrich: Data curation, writing–review and editing. D.C. Qian: Data curation, writing–review and editing. N.F. Saba: Resources, supervision, writing–review and editing. D.W. Bruner: Conceptualization, supervision, writing–review and editing. D.P. Jones: Conceptualization, resources, methodology, writing–review and editing. C. Xiao: Conceptualization, data curation, supervision, funding acquisition, project administration, writing–review and editing.

R.C. Eldridge would like to thank the Georgia Clinical and Translational Science Alliance (UL1TR002378 and KL2TR002381), and C. Xiao would like to thank the National Institute of Nursing Research (K99/R00NR014587 and R01NR015783) and the Winship Cancer Institute via the NCI (P30CA138292) for funding the conducted research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Georgia CTSA or the NIH.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).

1.
Ang
KK
,
Sturgis
EM
.
Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma
.
Semin Radiat Oncol
2012
;
22
:
128
42
.
2.
Comprehensive genomic characterization of head and neck squamous cell carcinomas
.
Nature
2015
;
517
:
576
82
.
3.
Hayes
DN
,
Van Waes
C
,
Seiwert
TY
.
Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors
.
J Clin Oncol
2015
;
33
:
3227
34
.
4.
Wilkie
MD
,
Lau
AS
,
Vlatkovic
N
,
Jones
TM
,
Boyd
MT
.
Metabolic signature of squamous cell carcinoma of the head and neck: consequences of TP53 mutation and therapeutic perspectives
.
Oral Oncol
2018
;
83
:
1
10
.
5.
Matoba
S
,
Kang
JG
,
Patino
WD
,
Wragg
A
,
Boehm
M
,
Gavrilova
O
, et al
.
p53 regulates mitochondrial respiration
.
Science
2006
;
312
:
1650
3
.
6.
Ward Patrick
S
,
Thompson Craig
B
.
Metabolic reprogramming: a cancer hallmark even warburg did not anticipate
.
Cancer Cell
2012
;
21
:
297
308
.
7.
Vander Heiden
MG
,
Cantley
LC
,
Thompson
CB
.
Understanding the Warburg effect: the metabolic requirements of cell proliferation
.
Science
2009
;
324
:
1029
33
.
8.
Vaupel
P
,
Schmidberger
H
,
Mayer
A
.
The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression
.
Int J Radiat Biol
2019
;
95
:
912
9
.
9.
Lu
J
.
The Warburg metabolism fuels tumor metastasis
.
Cancer Metastasis Rev
2019
;
38
:
157
64
.
10.
Sandulache
VC
,
Myers
JN
.
Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets
.
Head Neck
2012
;
34
:
282
90
.
11.
Khalid
OA
,
Claudiu
TS
,
Laurent
S
.
The Warburg effect and the hallmarks of cancer
.
Anticancer Agents Med Chem
2017
;
17
:
164
70
.
12.
Kapoor
V
,
McCook
BM
,
Torok
FS
.
An introduction to PET-CT imaging
.
Radiographics
2004
;
24
:
523
43
.
13.
Tantiwongkosi
B
,
Yu
F
,
Kanard
A
,
Miller
FR
.
Role of (18)F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma
.
World J Radiol
2014
;
6
:
177
91
.
14.
Feliciani
G
,
Fioroni
F
,
Grassi
E
,
Bertolini
M
,
Rosca
A
,
Timon
G
, et al
.
Radiomic profiling of head and neck cancer: (18)F-FDG PET texture analysis as predictor of patient survival
.
Contrast Media Mol Imaging
2018
;
2018
:
3574310
.
15.
Cruz-Gregorio
A
,
Martínez-Ramírez
I
,
Pedraza-Chaverri
J
,
Lizano
M
.
Reprogramming of energy metabolism in response to radiotherapy in head and neck squamous cell carcinoma
.
Cancers
2019
;
11
:
182
.
16.
Meijer
TWH
,
Kaanders
J
,
Span
PN
,
Bussink
J
.
Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy
.
Clin Cancer Res
2012
;
18
:
5585
94
.
17.
Zhong
JT
,
Zhou
SH
.
Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinoma
.
Oncotarget
2017
;
8
:
14133
46
.
18.
Jung
YS
,
Najy
AJ
,
Huang
W
,
Sethi
S
,
Snyder
M
,
Sakr
W
, et al
.
HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancer
.
Oncotarget
2017
;
8
:
51530
41
.
19.
Krupar
R
,
Robold
K
,
Gaag
D
,
Spanier
G
,
Kreutz
M
,
Renner
K
, et al
.
Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different
.
Virchows Arch
2014
;
465
:
299
312
.
20.
Liu
X
,
Locasale
JW
.
Metabolomics: a primer
.
Trends Biochem Sci
2017
;
42
:
274
84
.
21.
Yu
T
,
Jones
DP
.
Improving peak detection in high-resolution LC/MS metabolomics data using preexisting knowledge and machine learning approach
.
Bioinformatics
2014
;
30
:
2941
8
.
22.
Uppal
K
,
Walker
DI
,
Jones
DP
.
xMSannotator: an R package for network-based annotation of high-resolution metabolomics data
.
Anal Chem
2017
;
89
:
1063
7
.
23.
Liu
KH
,
Nellis
M
,
Uppal
K
,
Ma
C
,
Tran
V
,
Liang
Y
, et al
.
Reference standardization for quantification and harmonization of large-scale metabolomics
.
Anal Chem
2020
;
92
:
8836
44
.
24.
Li
S
,
Park
Y
,
Duraisingham
S
,
Strobel
FH
,
Khan
N
,
Soltow
QA
, et al
.
Predicting network activity from high throughput metabolomics
.
PLoS Comput Biol
2013
;
9
:
e1003123
.
25.
Uppal
K
,
Walker
DI
,
Liu
K
,
Li
S
,
Go
YM
,
Jones
DP
.
Computational metabolomics: a framework for the million metabolome
.
Chem Res Toxicol
2016
;
29
:
1956
75
.
26.
Osborn
MP
,
Park
Y
,
Parks
MB
,
Burgess
LG
,
Uppal
K
,
Lee
K
, et al
.
Metabolome-wide association study of neovascular age-related macular degeneration
.
PLoS One
2013
;
8
:
e72737
.
27.
Xiao
C
,
Eldridge
RC
,
Beitler
JJ
,
Higgins
KA
,
Chico
CE
,
Felger
JC
, et al
.
Association among glucocorticoid receptor sensitivity, fatigue, and inflammation in patients with head and neck cancer
.
Psychosom Med
2020
;
82
:
508
16
.
28.
Lingen
MW
,
Xiao
W
,
Schmitt
A
,
Jiang
B
,
Pickard
R
,
Kreinbrink
P
, et al
.
Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas
.
Oral Oncol
2013
;
49
:
1
8
.
29.
Ang
KK
,
Harris
J
,
Wheeler
R
,
Weber
R
,
Rosenthal
DI
,
Nguyen-Tân
PF
, et al
.
Human papillomavirus and survival of patients with oropharyngeal cancer
.
N Engl J Med
2010
;
363
:
24
35
.
30.
Accardi
CJ
,
Walker
DI
,
Uppal
K
,
Quyyumi
AA
,
Rohrbeck
P
,
Pennell
KD
, et al
.
High-Resolution metabolomics for nutrition and health assessment of armed forces personnel
.
J Occup Environ Med
2016
;
58
:
S80
8
.
31.
Chandler
JD
,
Hu
X
,
Ko
EJ
,
Park
S
,
Lee
YT
,
Orr
M
, et al
.
Metabolic pathways of lung inflammation revealed by high-resolution metabolomics (HRM) of H1N1 influenza virus infection in mice
.
Am J Physiol Regul Integr Comp Physiol
2016
;
311
:
R906
16
.
32.
Yu
T
,
Park
Y
,
Li
S
,
Jones
DP
.
Hybrid feature detection and information accumulation using high-resolution LC-MS metabolomics data
.
J Proteome Res
2013
;
12
:
1419
27
.
33.
Uppal
K
,
Soltow
QA
,
Strobel
FH
,
Pittard
WS
,
Gernert
KM
,
Yu
T
, et al
.
xMSanalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data
.
BMC Bioinformatics
2013
;
14
:
15
.
34.
Johnson
WE
,
Li
C
,
Rabinovic
A
.
Adjusting batch effects in microarray expression data using empirical Bayes methods
.
Biostatistics
2007
;
8
:
118
27
.
35.
Schrimpe-Rutledge
AC
,
Codreanu
SG
,
Sherrod
SD
,
McLean
JA
.
Untargeted metabolomics strategies—challenges and emerging directions
.
J Am Soc Mass Spectrom
2016
;
27
:
1897
905
.
36.
R Package for Biomarker Discovery, Network, and Data Exploratory Analysis [computer program]
.
Version 1.1.76. GitHub: GitHub
.
37.
SAS, Institute, Inc
.
Base SAS 9.4 procedures guide
. 2nd ed.
Cary, NC
:
SAS Institute Inc.
;
2012
.
38.
Zhou
J
,
Xu
B
,
Huang
J
,
Jia
X
,
Xue
J
,
Shi
X
, et al
.
1H NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma
.
Clin Chim Acta
2009
;
401
:
8
13
.
39.
Tiziani
S
,
Lopes
V
,
Gunther
UL
.
Early stage diagnosis of oral cancer using 1H NMR-based metabolomics
.
Neoplasia
2009
;
11
:
269
76
.
40.
Yonezwa
K
,
Nishiumii
S
,
Kitamoto-Matsuda
J
,
Fujita
T
,
Morimoto
K
,
Yamashita
D
, et al
.
Serum and tissue metabolomics of head and neck cancer
.
Cancer Genomics Proteomics
2013
;
10
:
233
8
.
41.
Gupta
A
,
Gupta
S
,
Mahdi
AA
.
1H NMR-derived serum metabolomics of leukoplakia and squamous cell carcinoma
.
Clin Chim Acta
2015
;
441
:
47
55
.
42.
Sandulache
VC
,
Ow
TJ
,
Pickering
CR
,
Frederick
MJ
,
Zhou
G
,
Fokt
I
, et al
.
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells
.
Cancer
2011
;
117
:
2926
38
.
43.
Semenza
GL
.
HIF-1: upstream and downstream of cancer metabolism
.
Curr Opin Genet Dev
2010
;
20
:
51
6
.
44.
Keck
MK
,
Zuo
Z
,
Khattri
A
,
Stricker
TP
,
Brown
CD
,
Imanguli
M
, et al
.
Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes
.
Clin Cancer Res
2015
;
21
:
870
81
.
45.
Zhu
G
,
Peng
F
,
Gong
W
,
She
L
,
Wei
M
,
Tan
H
, et al
.
Hypoxia promotes migration/invasion and glycolysis in head and neck squamous cell carcinoma via an HIF-1α-MTDH loop
.
Oncol Rep
2017
;
38
:
2893
900
.
46.
Nordsmark
M
,
Bentzen
SM
,
Rudat
V
,
Brizel
D
,
Lartigau
E
,
Stadler
P
, et al
.
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. an international multi-center study
.
Radiother Oncol
2005
;
77
:
18
24
.
47.
Fu
T
,
Coulter
S
,
Yoshihara
E
,
Oh
TG
,
Fang
S
,
Cayabyab
F
, et al
.
FXR regulates intestinal cancer stem cell proliferation
.
Cell
2019
;
176
:
1098
112
.
48.
Burotto
M
,
Szabo
E
.
PPARγ in head and neck cancer prevention
.
Oral Oncol
2014
;
50
:
924
9
.
49.
Guo
C
,
Su
J
,
Li
Z
,
Xiao
R
,
Wen
J
,
Li
Y
, et al
.
The G-protein-coupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway
.
Oncotarget
2015
;
6
:
34402
13
.
50.
Phelan
JP
,
Reen
FJ
,
Caparros-Martin
JA
,
O'Connor
R
,
O'Gara
F
.
Rethinking the bile acid/gut microbiome axis in cancer
.
Oncotarget
2017
;
8
:
115736
47
.
51.
Phelan
JP
,
Reen
FJ
,
Dunphy
N
,
O'Connor
R
,
O'Gara
F
.
Bile acids destabilise HIF-1α and promote anti-tumour phenotypes in cancer cell models
.
BMC Cancer
2016
;
16
:
476
.
52.
Moon
Y
,
Park
B
,
Park
H
.
Hypoxic repression of CYP7A1 through a HIF-1α- and SHP-independent mechanism
.
BMB Rep
2016
;
49
:
173
8
.
53.
Santos
CR
,
Schulze
A
.
Lipid metabolism in cancer
.
FEBS J
2012
;
279
:
2610
23
.
54.
Sherubin
EJ
,
Kannan
KS
,
Kumar
DN
,
Joseph
I
.
Estimation of plasma lipids and its significance on histopathological grades in oral cancer: prognostic significance an original research
.
J Oral Maxillofac Pathol
2013
;
17
:
4
9
.
55.
Kumar
P
,
Augustine
J
,
Urs
A
,
Arora
S
,
Gupta
S
,
Mohanty
V
.
Serum lipid profile in oral cancer and leukoplakia: correlation with tobacco abuse and histological grading
.
J Cancer Res Ther
2012
;
8
:
384
8
.
56.
Lohe
VK
,
Degwekar
SS
,
Bhowate
RR
,
Kadu
RP
,
Dangore
SB
.
Evaluation of correlation of serum lipid profile in patients with oral cancer and precancer and its association with tobacco abuse
.
J Oral Pathol Med
2010
;
39
:
141
8
.
57.
Garg
D
,
Sunil
MK
,
Singh
PP
,
Singla
N
,
Rani
SR
,
Kaur
B
.
Serum lipid profile in oral precancer and cancer: a diagnostic or prognostic marker?
J Int Oral Health
2014
;
6
:
33
39
.
58.
Acharya
S
,
Rai
P
,
Hallikeri
K
,
Anehosur
V
,
Kale
J
.
Serum lipid profile in oral squamous cell carcinoma: alterations and association with some clinicopathological parameters and tobacco use
.
Int J Oral Maxillofac Surg
2016
;
45
:
713
20
.
59.
Li
G
,
Da
M
,
Zhang
W
,
Wu
H
,
Ye
J
,
Chen
J
, et al
.
Alteration of serum lipid profile and its prognostic value in head and neck squamous cell carcinoma
.
J Oral Pathol Med
2016
;
45
:
167
72
.
60.
Krishna
S
,
Brown
N
,
Faller
DV
,
Spanjaard
RA
.
Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells
.
Laryngoscope
2002
;
112
:
645
50
.
61.
Psyrri
A
,
Seiwert
TY
,
Jimeno
A
.
Molecular pathways in head and neck cancer: EGFR, PI3K, and more.
Am Soc Clin Oncol Educ Book
2013
;
246
55
.
62.
Landor
SKJ
,
Mutvei
AP
,
Mamaeva
V
,
Jin
S
,
Busk
M
,
Borra
R
, et al
.
Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms
.
Proc Natl Acad Sci U S A
2011
;
108
:
18814
9
.
63.
Kraehling
JR
,
Chidlow
JH
,
Rajagopal
C
,
Sugiyama
MG
,
Fowler
JW
,
Lee
MY
, et al
.
Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells
.
Nat Commun
2016
;
7
:
13516
.
64.
Byeon
HK
,
Ku
M
,
Yang
J
.
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer
.
Exp Mol Med
2019
;
51
:
1
14
.
65.
Yu
W
,
Chen
Y
,
Putluri
N
,
Coarfa
C
,
Robertson
MJ
,
Putluri
V
, et al
.
Acquisition of Cisplatin resistance shifts head and neck squamous cell carcinoma metabolism toward neutralization of oxidative stress
.
Cancers
2020
;
12
:
1670
.
66.
Li
X
,
Lu
Y
,
Lu
H
,
Luo
J
,
Hong
Y
,
Fan
Z
.
AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab
.
Oncotarget
2015
;
6
:
11507
18
.

Supplementary data